REPRESENTATIVE EXPERIENCE
Goody Agahi
Represented Malbon Golf, Inc. in its Series A investment by Avenir Growth Capital.
Represented I Am Beyond, LLC dba Beyond Yoga in connection with its acquisition by Levi Strauss & Co. (NYSE: LEVI).
Represented Drips, LLC in connection with a minority recapitalization by Accel-KKR.
Represented Environmental Intelligence, LLC in connection with its acquisition by Montrose Environmental Group, Inc. (NYSE: MEG).
Represented PreZero US, Inc. in connection with multiple acquisitions, including the acquisition of Roplast Industries, LLC.
Represented Winc, Inc. in connection with its acquisition of substantially all of the assets of Natural Merchants, Inc.
Represented Paradigm Holdings Group, LLC in connection with a majority recapitalization by Hamilton Robinson Capital Partners.
Represented Aerospace Engineering, Corp. in connection with its acquisition by Trive Capital Partners.
Represented Permit Advisors, Inc. in connection with its acquisition by Milrose Consultants.
Represented Boardriders Inc. in connection with its sale of the Xcel wetsuit brand to ZG Collective.
Represented Blenders Eyewear, LLC in connection with its acquisition by Safilo Group.
Represented RPM Consolidated Services, Inc. in connection with its acquisition by Odyssey Logistics & Technology Corporation.
Represented Host Compliance LLC in connection with its acquisition by Granicus, LLC.
Represented CAP Diagnostics, LLC (dba Pathnostics) in connection with its acquisition by Water Street Healthcare Partners.
Represented Host Compliance, LLC in connection with its acquisition of Bear Cloud Software, LLC.
Represented TravisMathew, LLC in connection with its acquisition by Callaway Golf Company.
Represented Omega Biosystems, Inc. in connection with its acquisition by BD Biosciences.
Represented Gatekeeper Systems, Inc. in connection with its acquisition by Hammond, Kennedy, Whitney & Company, Inc.
Represented Blockade Medical, LLC in connection with its acquisition by Balt, Inc.
Represented Santen Pharmaceuticals in connection with its acquisition of Merck’s ophthalmic assets.
Represented Questcor Pharmaceuticals in connection with its acquisition of rights to develop Synacthen from Novartis Pharma.
